Better Buy: Pfizer vs. Bristol Myers Squibb
Pfizer (NYSE: PFE) will look like a much different company within a few months as it spins off Upjohn and merges the unit with Mylan. Bristol Myers Squibb (NYSE: BMY) is still integrating Celgene after acquiring the biotech in November. Both Pfizer and BMS have seen their stocks plunge close to 30% this year then make strong rebounds.